Low and high hemoglobin levels were associated with increased risk for dementia, white matter hyperintensity volume, and structural connectivity.
In a study, autoantibodies to the erythropoietin receptor were detected in some patients on maintenance hemodialysis, and this correlated with hyporesponsiveness to erythropoiesis-stimulating agents.
In anemic kidney disease patients with cancer, reviewers suggest using ESA to minimize symptoms without exceeding a hemoglobin target of 10 g/dL.
Over a median 5.1 years, similar proportions of patients who received monthly methoxy polyethylene glycol epoetin beta arm and a reference group treated with conventional ESAs experienced major cardiovascular events and death.
Meta-analysis reveals no statistically significant increase in the risks of infection, cardiovascular events, hospitalizations, or death with the use of high-dose parenteral iron.
The first HIF-PHI, roxadustat, was recently approved in China.
Measuring health-related quality of life should be routine patient care, according to a new review.
Recent review says findings from the PIVOTAL trial should allay concerns about the use of intravenous iron therapy in patients with end-stage renal disease suffering from anemia.
In a study of chronic kidney disease patients undergoing vascular access surgery for hemodialysis, severe preoperative anemia was associated with worse outcomes.
The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.